ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CNP Clinphone

134.25
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Clinphone LSE:CNP London Ordinary Share GB00B0ZL4M73 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 134.25 0.00 00:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
  -
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 134.25 GBX

Clinphone (CNP) Latest News

Real-Time news about Clinphone (London Stock Exchange): 0 recent articles

Clinphone (CNP) Discussions and Chat

Clinphone (CNP) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Clinphone (CNP) Top Chat Posts

Top Posts
Posted at 13/6/2008 11:59 by parvez
Ah! things happening fast here!

Quintiles Transnational Corp released a statement in response to the Parexel
announcement saying that it may make an all-cash counter offer for the company,
which would be at a premium to the price per share offered by Parexel.

It confirmed that it was in discussions with the ClinPhone board, and said
it was currently conducting its due diligence on ClinPhone. A further
announcement will be made in due course, it said.
Posted at 13/6/2008 11:55 by parvez
miket, did you have a spreadbet? price now is above the bid price so expecting someone else to enter the fray? I only have 1500 so nothing to write home about!
Posted at 15/2/2008 20:29 by cockneyrebel
Looks like a bid :

DJ Parexel Confirms Preliminary Bid For ClinPhone >PRXL

DOW JONES NEWSWIRES

Parexel International Corp. (PRXL) confirmed Friday that it made a preliminary proposal to buy ClinPhone PLC (CNP.LN), and ClinPhone rejected the company's offer.

Reponding to recent movements in ClinPhone's share price, Parexel, a Boston contract research organization, said it is currently evaluating its options related to the Nottingham, U.K., clinical technology organization.

Shares of ClinPhone closed up nearly 17% on the London Stock Exchange Friday, rising GBP12.25 to GBP84.75.

Parexel said there can't be any certainty it will make a new offer for ClinPhone, though it did note that any offer would likely be solely in cash.

Shares of Parexel recently traded down $1.55, or 2.7%, at $55.65.
Posted at 17/1/2008 12:36 by nurdin
Hardly a glorified telephone service WJC...if they were just that then they wouldnt be the biggest service providers of that elk in Europe.True the data is collected through dedicated and and automated telephone lines,but being in a highly regulated industry the information gathered has to be properly analysed and correlated statistically.Errors in voice data have also to be analysed and interpreted.

Also central to their operation is a highly sophisticated software that they have spent 5 years developing.They also employ an army of staticians whose prime function is to interepret the data and develop optimum testing strategies.

The latest in the clinical trial field is adaptive trials which allow trials to be conducted on diffrent dosages than the norm.I understand this procedure is based on Bayesian probablity calculus and CNP have a lead in this technology.They have 2 adaptive trials underway currently and the Company sees this technology being taken up very fast going forward

I feel the barriers to entry here are very high...
Posted at 02/8/2007 13:08 by barbra2
Thanks, Pugugly. I have not looked at this company previously but the steep decline in share price over the last 2 days caught my attention. Just thought that there may be potential to make a quick buck when it's oversold.
Posted at 01/8/2007 00:21 by vision88
ClinPhone sees FY profits significantly below market expectations:


If you believe there is to be no recovery here you would im sure bail out now , but i can not see this hic up in the share price lasting much more than 6 months at the most , 2008 the share price may well be over the £2.00p mark, i remain optomistic target 2008/09 £3.50p
Posted at 10/5/2007 06:27 by jsteveuk
Anyone else into CNP?



Good news this morning re. EDC with Kendle.
Posted at 27/10/2006 07:45 by hedgehunter
Maiden profit reported at ClinPhone
an ADVFN competitor
ClinPhone moved into profit in the first half of the year, driven by growing demand for the technology its designs for drug makers to use in clinical trials.

The results, the first presented since the company floated on the London Stock Exchange in June, revealed pretax profits of £1.8m, or 2.4p per share in the six months to end-Aug. In the same period last year pretax losses came in at £90,000, or 0.14p per share.

Contracted orders increased 18% to £36.7m, helping to lift revenues 32%, to £20.7m. Average order values increased by 24%.

ClinPhone said demand for new technologies in clinical trials is growing, and estimates that 80% of the market is still using paper-based methods.

'The industry is increasingly recognising the benefits of using technology to manage the clinical trials process,' CEO, Steve Kent, said in a statement.

'The market continues to adopt technology solutions at a rapid pace and demand for our products and services continues to grow.

'We look forward to the rest of the year with confidence,' he added.

Yesterday, ClinPhone announced the acquisition of California-based Datalabs for up to 36.5 mln stg. The company designs so-called electronic data capture technology aimed at the clinical trials market.

Shares in the company, which floated at 148p, closed Thursday at 218p, giving the group a market value of £139m.





Powered by IST's
Posted at 23/9/2006 09:27 by hedgehunter
A good historical piece from UK analyst.com...........

Clinphone - Buy

Clinphone's debut clearly proves that there is strong interest in the new issues market for the right sort of company. Rising 15% from a placing price of 148p on its first day of dealings, the specialist supplier of technology solutions, Clinphone, finished the day at 173p. The group successfully managed to raise 20 million of new money and place shares worth 39.1 million pounds for selling shareholders, raising a total of around 60 million pounds. However, CEO Steve Kent admits that it was extremely disheartening to launch a road show in the midst of a market fallout. 'It was worrying as companies were pulling floats by the day as we went around trying to raise money and surprisingly, institutions were more than willing to fund our IPO' says Kent. At 148p, the company came to market with a valuation of 94.1 million pounds. The placing was fully underwritten by Investec. AIM quoted HgCapital chose to realise a portion of its investment, netting 5.8 million pounds in cash. It will retain a 6.2% stake in the company. Clinphone has delivered a 37% return on investment for HG Capital over the last nine years.

Operations - Headquartered in Nottingham, the group was founded in 1993 by two doctors - Neil Rotherham and Jonathan Engler. The founders saw an opportunity to improve the clinical trials process by providing centralised support services that could be available 24 hours a day, 7 days a week, throughout the year. The original concept soon developed into a global business that now provides e-clinical solutions to 88 countries, in 77 languages, handing over 1000 clinical trials every month.

The market in which ClinPhone operates is large and growing, driven by the expanding use of technology and the increasing complexity of clinical trials. The vast majority of data collection and reporting in this market continues to be done using expensive paper based, labour intensive methods. It was estimated in 2004 that just 5-8% of all clinical trials used technology for data capture. This is forecasted to reach 40% by 2009. ClinPhone's technology reduces the cost and duration of running clinical trials and improves the accuracy and consistency of data collected. The directors believe that ClinPhone's technology could drive the transfer from paper to online in the market.

Over the last 10 years, the group has developed technology around the use of the telephone and internet to efficiently randomise patients, manage trial medications and to collect, aggregate, analyse and report clinical trial data in real time. It has a strong presence in the industry and serves 16 to 20 of the largest pharmaceutical companies by revenue. To date it has collected data from over 90,000 investigator sites.

Business Development - In the financial year to February 2006, the group brought in sales of 33.9 million pounds, an increase of 17.7% on 2005. For the period to February, the group completed 411 live studies and employed 538 employees. Pre-tax profits for the year to February 2006 came in at 947,000 pounds while profits in 2005, came in at 3.4 million pounds. The numbers have been affected by a one off charge against share based payments (the conversion of share options to shares). The charge going ahead for new share options granted is estimated to be around a million pounds, therefore pre-tax profits (after the share based payment and amortisation) could easily come in around 2 million pounds. However, if we view amortisation and share based payments as non-cash items, the group recorded an adjusted operating profit of 5.7 million pounds.
The group faces a higher US corporate tax charge of around 48% as one of its subsidiaries is based in America. The order book for the current year stands at 49.6 million pounds, underpinning sales growth for 2007. The group has net cash of just over 2 million pounds.

ClinPhone will use a large part of the funds raised to reduce its debt pile, part of it goes to HSBC and the remaining to private equity investors. This will serve to secure diversified ownership. The group does not intend to come back to the market to raise any further money and is confident of funding its operations through cash flow. With nearly 80% of the market yet to capture, Clinphone is keen on introducing new services for its customers. It intends to invest heavily in research and development and will look for paper based acquisitions to fuel growth. The group will also concentrate on increasing licensing revenue.

Management - Founders, Jonathan Engler and Neil Rotherham have sold part of their stakes for over 5 million pounds each. They currently have no involvement with the company. CEO, Steve Kent worked in various financial positions in various industries before leading an MBO in 1995 for Workplace Technologies. He joined ClinPhone in 2002. Scott Brown, CFO, qualified at Grant Thornton and subsequently worked at ABN Amro in Hong Kong. Non-Executive Chairman, Edwin Moses serves as both exec and non-executive director on the board of health related companies like Biofusion and Phoqus Group.

Investment Conclusion - Clinphone is the first to bring this technology to the clinical trials market. It is by far the largest company operating in a very niche sector across the world and faces competition only from country specific firms. The next few years will see the company gaining market share across the world. The analysts and the company were reluctant to give us an indication of sales or profits for the next few years. If we ignore amortisation and share based payments and assume Clinphone can bring in post tax profits of around 6 million pounds in the year to 2007 (and we believe our estimates are conservative), it trades on a current year PE of 16. This could easily fall to a single digit PE in 2008. At 173p, we believe Clinphone is a buy offering real value in the current new issues market.

Contact Details - Investec - 020 7597 5197
Posted at 26/6/2006 23:45 by hedgehunter
Over the last 10 years, the group has developed technology around the use of the telephone and internet to efficiently randomise patients, manage trial medications and to collect, aggregate, analyse and report clinical trial data in real time. It has a strong presence in the industry and serves 16 to 20 of the largest pharmaceutical companies by revenue. To date it has collected data from over 90,000 investigator sites.

In the financial year to February 2006, the group brought in sales of 33.9 million pounds, an increase of 17.7% on 2005. For the period to February, the group completed 411 live studies and employed 538 employees. Pre-tax profits for the year to February 2006 came in at 947,000 pounds while profits in 2005, came in at 3.4 million pounds. The numbers have been affected by a one off charge against share based payments (the conversion of share options to shares). The charge going ahead for new share options granted is estimated to be around a million pounds, therefore pre-tax profits (after the share based payment and amortisation) could easily come in around 2 million pounds. However, if we view amortisation and share based payments as non-cash items, the group recorded an adjusted operating profit of 5.7 million pounds.
Clinphone share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com